Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) In Vitro DMPK Assay Services
Are you currently facing long drug development cycles, unpredictable preclinical data, or challenges in accurately predicting human drug responses? Our Creative Biolabs NHP In Vitro DMPK Assays help you accelerate drug discovery and obtain more translatable data by leveraging advanced in vitro models and a deep understanding of biopharmaceutical development. We provide a crucial bridge between preclinical and clinical stages, reducing the risk of costly failures in human trials.
Introduction to NHP In Vitro DMPK Assays
Non-human primates are genetically and immunologically closer to humans than other preclinical species, making them an indispensable tool in the development of biologics and advanced therapies. As demonstrated by published data, NHPs are often the only species that show therapeutic target cross-reactivity, making them a critical resource for predicting concentration-effect relationships and setting safe first-in-human doses. By utilizing NHP-based in vitro models, we provide data that more accurately reflects the human physiological response, enhancing the confidence in your drug candidate's potential.
What Our Service Is
Our comprehensive in vitro DMPK services with NHP-derived matrices are designed to help you de-risk your projects by providing early insights into a drug candidate's fate within the body. These services evaluate key ADME parameters using high-quality NHP biological samples.
- Microsomal & Hepatocyte Stability: We assess the metabolic stability of your compound in NHP liver fractions, a key step in predicting its half-life and clearance.
- Cytochrome P450 (CYP) & UGT Inhibition/Induction: Our assays determine the potential of your compound to inhibit or induce major drug-metabolizing enzymes, crucial for assessing the risk of drug-drug interactions.
- Plasma Protein Binding (PPB) Assays: We measure the extent to which your compound binds to plasma proteins, a critical factor influencing its distribution and free drug concentration.
- Transporter Substrate/Inhibition Screening: These assays help identify if your compound is a substrate for, or an inhibitor of, key drug transporters, which impacts its absorption and distribution.
- Metabolite Identification & Reaction Phenotyping: We can identify the primary metabolites of your compound and the specific enzymes responsible for their formation.
Why Choose Us?
Navigating the complexities of modern drug development, especially with novel modalities like gene therapies, requires precise and reliable data. Our approach addresses key pain points by providing high-fidelity NHP data that minimizes the unpredictability often associated with non-translatable preclinical models. We help you move from a state of uncertainty to a position of confidence, providing the data needed for solid, science-based decisions.
Fig.1 NHP PK and toxicology assessments show no severe adverse events associated with a humanized anti-CD47 antibody.1
Key Benefits of Our Service
At Creative Biolabs, we combine extensive expertise with a commitment to scientific excellence to deliver exceptional value. Our non-human primate services offer unique advantages that are critical for today's drug development landscape. We leverage our deep knowledge of DMPK and biopharmaceutical development to provide insights that go beyond simple data points.
- Extensive NHP Resources: Our access to a robust supply of high-quality NHP biological matrices ensures that we can support a wide range of study designs and timelines.
- Expert-Driven Customization: We offer fully customizable assay designs, tailoring each study to the specific needs of your compound and project goals.
- Exceptional Response Speed: Our streamlined processes and dedicated team allow for a faster turnaround time (TAT) on studies, helping you meet aggressive development timelines.
- Comprehensive Reporting: Every study concludes with an in-depth report that provides not just raw data, but also expert analysis and contextual interpretation, enabling you to make informed decisions.
- Published data and our experience with biopharmaceutical partners show that our services provide a clearer path to the clinic, helping you navigate the complexities of biodistribution, immunogenicity, and drug clearance.
How Creative Biolabs' NHP In Vitro DMPK Assays Can Assist Your Project?
Our services are designed to be a seamless extension of your research, providing the critical data needed to advance your project. We offer specific deliverables and key problem-solving capabilities to help you overcome the challenges of drug development.
01
Required Starting Materials
02
Study Design & Planning
03
Sample Preparation & Assay Execution
04
Sample Analysis & Data Generation
05
Data Interpretation & Reporting
Key Deliverables
- Comprehensive Laboratory Report
- Analyzed Raw Data Files
- Methodology and Study Protocol
- Expert Scientific Interpretation and Recommendations
Capabilities & Partnerships
Service-Specific Data
Our commitment to excellence is reflected in our robust capabilities and strategic partnerships.
- Annual Sample Size: Over 50,000 samples processed annually for NHP PK studies.
- Turnaround Time (TAT): Typical TAT of 2-4 weeks from sample collection to final data report.
- Pass Rate: Consistently >98% success rate for established methods.
Our Valued Partners
Frequently Asked Questions
Q: Why do I need to use NHP in vitro assays instead of other animal models like rats or dogs?
A: While rodent models are useful for early-stage screening, they often lack the genetic and metabolic similarity to humans that NHPs possess. For complex biologics and gene therapies, NHP models can provide data on target cross-reactivity and metabolic pathways that are essential for accurate human dose prediction and safety assessment, as published data suggests. Using NHP models can significantly reduce the risk of clinical failure.
Q: Can your assays predict potential immunogenicity in humans?
A: While in vitro assays don't fully predict the complex immune response in vivo, they can provide valuable insights. By utilizing NHP matrices, we can assess interactions that are more translatable to humans, helping you identify potential issues early. We recommend a consultation to discuss how our assays can support your specific immunogenicity risk assessment strategy.
Q: What is the typical turnaround time for these services?
A: Our standard turnaround time for most NHP in vitro DMPK assays is between 4 to 6 weeks. This can vary based on the project's complexity, the number of compounds, and the specific assays required. We prioritize efficiency to help you maintain your project timelines.
Q: How do you ensure the quality and consistency of the NHP biological matrices you use?
A: We partner with trusted, accredited suppliers to ensure a consistent and high-quality source of NHP biological matrices. All samples undergo rigorous quality control checks before use to guarantee the reliability and reproducibility of our assay results.
Q: How does this service compare to in vivo NHP studies?
A: Our in vitro assays are a highly cost-effective and rapid alternative to in vivo studies. They allow you to screen multiple compounds and gather critical data on metabolic fate and drug-drug interactions before committing to more resource-intensive in vivo work. They are a powerful tool for a science-based decision to select the best candidates to move forward.
Contact Us
Creative Biolabs is your trusted partner for high-quality, translatable DMPK services. Our NHP in vitro assays provide the critical data you need to make confident, science-driven decisions, ultimately accelerating your path to the clinic. Contact Our Team for More Information and to Discuss Your Project.
Reference
- Liu, Jie, et al. "Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential." PloS one 10.9 (2015): e0137345. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1371/journal.pone.0137345